AKESO BIOPHARMA
BiotechAKESO BIOPHARMA is a biotechnology company focused on Oncology, Gastroenterology, Immunology.
FDA Novel Drug Designations
(2025)See 1 novel approval →
AKESO BIOPHARMA at a Glance
- Fast trial execution (28 months median completion)
AKESO BIOPHARMA's Key Drugs
AKESO BIOPHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
AKESO BIOPHARMA's Recent FDA Approvals
AKESO BIOPHARMA secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
AKESO BIOPHARMA's Therapeutic Areas
AKESO BIOPHARMA's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Gastroenterology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AKESO BIOPHARMA's Top Competitors
AKESO BIOPHARMA's closest competitors by therapeutic-area and drug-target overlap include BAUSCH, Pfizer, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AKESO BIOPHARMA Pipeline Snapshot
AKESO BIOPHARMA has 136 active clinical programs from ClinicalTrials.gov — 34 Phase 3, 44 Phase 2 and 58 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 9/33 completed
- • Speed: 28 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2025-04-23
- Latest
- 2026-08-31
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges